Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVXLNASDAQ:CDMONASDAQ:CRONNASDAQ:HURA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVXLAnavex Life Sciences$9.14-0.9%$8.52$4.00▼$14.44$783.61M0.681.18 million shs194 shsCDMOAvid Bioservices$12.50+0.1%$12.50$6.61▼$12.51$799.18M1.391.43 million shs3.07 million shsCRONCronos Group$1.92+0.3%$1.94$1.60▼$2.54$738.58M1.041.33 million shs681 shsHURATuHURA Biosciences$2.22-0.6%$3.23$1.80▼$7.93$97.19M0.23258,695 shs1,892 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVXLAnavex Life Sciences-2.74%-0.86%+22.44%+14.96%+118.48%CDMOAvid Bioservices0.00%0.00%0.00%0.00%+75.00%CRONCronos Group+0.53%+2.14%-3.54%+6.70%-18.03%HURATuHURA Biosciences+0.45%-11.86%-28.30%-23.37%+222,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVXLAnavex Life Sciences3.8509 of 5 stars3.70.00.04.72.90.80.6CDMOAvid Bioservices0.9106 of 5 stars1.00.00.04.51.51.70.6CRONCronos Group2.4808 of 5 stars0.05.00.00.02.60.02.5HURATuHURA Biosciences1.4962 of 5 stars3.70.00.00.02.00.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVXLAnavex Life Sciences 3.33Buy$44.00381.40% UpsideCDMOAvid Bioservices 2.00Hold$12.25-1.96% DownsideCRONCronos Group 0.00N/AN/AN/AHURATuHURA Biosciences 3.40Buy$12.67471.60% UpsideCurrent Analyst Ratings BreakdownLatest HURA, CDMO, AVXL, and CRON Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/23/2025HURATuHURA BiosciencesBrookline Capital ManagementSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/16/2025HURATuHURA BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.004/7/2025AVXLAnavex Life SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$42.00 ➝ $42.004/7/2025AVXLAnavex Life SciencesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$46.00 ➝ $46.004/3/2025HURATuHURA BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$13.00 ➝ $12.00(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVXLAnavex Life SciencesN/AN/AN/AN/A$1.42 per shareN/ACDMOAvid Bioservices$139.91M5.71$0.15 per share80.92$3.02 per share4.14CRONCronos Group$117.61M6.28N/AN/A$2.90 per share0.66HURATuHURA BiosciencesN/AN/AN/AN/A$0.34 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVXLAnavex Life Sciences-$43M-$0.55N/AN/AN/AN/A-40.93%-36.38%8/5/2025 (Estimated)CDMOAvid Bioservices-$140.75M-$2.39N/AN/AN/A-101.07%-33.18%-8.45%9/8/2025 (Estimated)CRONCronos Group$41.08M$0.1314.7363.8332.3139.69%-0.07%-0.07%8/6/2025 (Estimated)HURATuHURA Biosciences-$21.68MN/A0.00∞N/AN/A291.69%122.09%N/ALatest HURA, CDMO, AVXL, and CRON EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025HURATuHURA Biosciences-$0.13-$0.15-$0.02-$0.15N/AN/A5/13/2025Q2 2025AVXLAnavex Life Sciences-$0.16-$0.13+$0.03-$0.13N/AN/A5/8/2025Q1 2025CRONCronos Group$0.01$0.02+$0.01$0.02$45.44 million$33.62 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVXLAnavex Life SciencesN/AN/AN/AN/AN/ACDMOAvid BioservicesN/AN/AN/AN/AN/ACRONCronos GroupN/AN/AN/AN/AN/AHURATuHURA BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVXLAnavex Life SciencesN/A6.746.74CDMOAvid Bioservices3.581.300.92CRONCronos GroupN/A27.8026.75HURATuHURA BiosciencesN/A3.003.00Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVXLAnavex Life Sciences31.55%CDMOAvid Bioservices97.16%CRONCronos Group8.71%HURATuHURA Biosciences0.62%Insider OwnershipCompanyInsider OwnershipAVXLAnavex Life Sciences11.00%CDMOAvid Bioservices3.05%CRONCronos Group6.90%HURATuHURA Biosciences0.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVXLAnavex Life Sciences4085.37 million75.98 millionOptionableCDMOAvid Bioservices32063.96 million62.01 millionOptionableCRONCronos Group450385.68 million359.07 millionOptionableHURATuHURA BiosciencesN/A43.68 million43.59 millionN/AHURA, CDMO, AVXL, and CRON HeadlinesRecent News About These CompaniesTuHURA Biosciences, Inc. Announces Inclusion in the Russell 3000® and Russell 2000® Indexes1 hour ago | finance.yahoo.comTuHURA Biosciences, Inc. Announces Inclusion in the Russell 3000® and Russell 2000® Indexes1 hour ago | prnewswire.comTuHURA Biosciences, Inc.: TuHURA Biosciences Completes Acquisition of KinetaJune 30 at 6:11 PM | finanznachrichten.deTuHURA Biosciences Completes Acquisition of KinetaJune 30 at 8:50 AM | prnewswire.comAnalysts Set TuHURA Biosciences, Inc. (NASDAQ:HURA) Target Price at $12.67June 27, 2025 | americanbankingnews.comEquities Analysts Issue Forecasts for HURA Q2 EarningsJune 26, 2025 | americanbankingnews.comTuHURA Biosciences, Inc. and Kineta, Inc. Stockholders Approve Proposed Merger and All Related Proposals - MorningstarJune 25, 2025 | morningstar.comMTuHURA initiates phase 3 trial for cancer immunotherapy drugJune 25, 2025 | uk.investing.comTuHURA Biosciences Initiates Its Phase 3 Accelerated Approval Trial of IFx-2.0 as an Adjunctive Therapy to Keytruda® (pembrolizumab) in First Line Treatment for Advanced or ...June 25, 2025 | morningstar.comMBrookline Capital Management Predicts HURA Q2 EarningsJune 25, 2025 | marketbeat.comTuHURA Biosciences (NASDAQ:HURA) Raised to Strong-Buy at Brookline Capital ManagementJune 25, 2025 | americanbankingnews.comTuHURA Biosciences, Inc. (NASDAQ:HURA) Receives Consensus Recommendation of "Buy" from BrokeragesJune 24, 2025 | marketbeat.comTuHURA Biosciences Initiates Its Phase 3 Accelerated Approval Trial of IFx-2.0 as an Adjunctive Therapy to Keytruda® (pembrolizumab) in First Line Treatment for Advanced or Metastatic Merkel Cell CarcinomaJune 24, 2025 | prnewswire.comTuHURA Biosciences (NASDAQ:HURA) Upgraded by Brookline Capital Management to "Strong-Buy" RatingJune 24, 2025 | marketbeat.comTuhura Biosciences Surges After-Hours As Investors Bet On Kineta Merger, Cancer Drug PipelineJune 23, 2025 | msn.comTuHURA Biosciences, Inc. and Kineta, Inc. Stockholders Approve Proposed Merger and All Related ProposalsJune 23, 2025 | prnewswire.comTuHURA Biosciences announces executive salary increasesJune 14, 2025 | uk.investing.comTuHURA Biosciences (NASDAQ:HURA) Downgraded by Wall Street Zen to "Sell"June 14, 2025 | marketbeat.comTuHURA Biosciences Amid Nasdaq Composite VolatilityJune 13, 2025 | kalkinemedia.comKTuHURA Biosciences Approves Executive Salary IncreasesJune 12, 2025 | tipranks.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HURA and VIGL on Behalf of ShareholdersJune 9, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHURA, CDMO, AVXL, and CRON Company DescriptionsAnavex Life Sciences NASDAQ:AVXL$9.14 -0.08 (-0.87%) As of 09:32 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.Avid Bioservices NASDAQ:CDMO$12.50 +0.02 (+0.12%) Closing price 02/5/2025Extended Trading$12.50 0.00 (0.00%) As of 02/5/2025 04:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Avid Bioservices, Inc. operates as a contract development and manufacturing organization for the biotechnology and biopharmaceutical industries in the United States. It provides process development and current good manufacturing practice clinical and commercial manufacturing services of biologics, including clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, regulatory submission and support, upstream and downstream development and optimization, analytical methods development, cell line development, testing, and characterization services. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was incorporated in 1981 and is based in Tustin, California.Cronos Group NASDAQ:CRON$1.92 +0.01 (+0.26%) As of 09:31 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.TuHURA Biosciences NASDAQ:HURA$2.22 -0.01 (-0.63%) As of 09:31 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.TuHURA Biosciences, Inc. (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced or metastatic Merkel Cell Carcinoma. In addition to its innate immune response agonist candidates, TuHURA is leveraging its Delta receptor technology to develop first-in-class bi-specific ADCs, and PDCs targeting Myeloid Derived Suppressor Cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s $100M Nuclear OS Pact Boosts Bullish Case Joby Stock Soars as Piloted Flights in Dubai Signal a New Era Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500 S&P 500 All-Time Highs: 5 Catalysts Driving It Higher The Top Insider Sells From Q2: Buy, Sell, or Hold? 5 High-Yielding ETFs to Buy and Hold Forever Why BigBear.ai Could Rally 100% and Catch Palantir Soon Why McCormick Stock Could Soar After Durables Data Surprise Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
